Research guide · Published July 22, 2026 · Sources checked July 22, 2026
GLP-1, GIP, and glucagon receptors explained
GLP-1R, GIPR, and GCGR are distinct class B G-protein-coupled receptors. Multi-agonist peptides can engage more than one of them, but catalog labels do not change official receptor nomenclature.
Short answer
GLP-1R responds to glucagon-like peptide-1, GIPR to glucose-dependent insulinotropic polypeptide, and GCGR to glucagon. ‘GLP-2’ and ‘GLP-3’ are catalog shorthand here; GLP-2 is also the name of a separate endogenous hormone, while ‘GLP-3 receptor’ is not the name of the retatrutide target set.
Evidence boundary: This is a nomenclature and receptor-science guide, not a statement of therapeutic equivalence or a human-use guide. Catalog materials are supplied only for qualified in vitro laboratory research and are not for human or animal use.
Comparison at a glance
| Receptor | Endogenous ligand | Appears in this catalog research | Interpretive caution |
|---|---|---|---|
| GLP-1R | GLP-1 | Semaglutide, tirzepatide, retatrutide | Activity varies with peptide design and assay system |
| GIPR | GIP | Tirzepatide, retatrutide | Species and signaling-bias findings require assay context |
| GCGR | Glucagon | Retatrutide | GCGR activity is one component of a multi-receptor design |
| GLP-2R | GLP-2 | Not the intended target behind the catalog label GLP-2 | Do not conflate tirzepatide with endogenous GLP-2 biology |
How to interpret the comparison
Cryo-EM and receptor-assay studies can describe binding geometry and signaling under defined conditions. They do not establish clinical outcomes or confirm the identity of an uncited batch.
Potency values should only be compared when assay conditions, receptor species, expression system, and readout are sufficiently aligned.
Primary sources
- Zhang et al., Cell Reports (2021) — Cryo-EM structures and dynamics of semaglutide-bound GLP-1R–Gs complexes. DOI: 10.1016/j.celrep.2021.109374
- Willard et al., JCI Insight (2020) — Comparative receptor pharmacology describing tirzepatide's asymmetric dual agonism. DOI: 10.1172/jci.insight.140532
- Li et al., Cell Discovery (2024) — Structural study of retatrutide at GLP-1R, GIPR, and GCGR. DOI: 10.1038/s41421-024-00700-0
Continue in the research library
Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.